Axon Enterprise (NASDAQ:AXON) CEO Patrick Smith Sells 10,000 Shares

Axon Enterprise, Inc (NASDAQ:AXON) CEO Patrick Smith sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total value of $7,137,400.00. Following the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at approximately $2,165,474,312.68. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Axon Enterprise Price Performance

Shares of AXON opened at $727.41 on Thursday. The company has a market cap of $57.10 billion, a P/E ratio of 179.61, a PEG ratio of 27.75 and a beta of 1.41. The stock has a fifty day moving average price of $756.79 and a 200 day moving average price of $710.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a 12 month low of $422.21 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the previous year, the firm posted $1.20 EPS. The firm’s quarterly revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wolfe Research assumed coverage on Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating for the company. Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday. Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Finally, Northland Securities set a $800.00 price objective on Axon Enterprise in a report on Tuesday, August 5th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds have recently modified their holdings of the stock. Sheets Smith Investment Management purchased a new stake in shares of Axon Enterprise during the third quarter valued at $510,000. Teamwork Financial Advisors LLC lifted its holdings in shares of Axon Enterprise by 233.1% during the third quarter. Teamwork Financial Advisors LLC now owns 18,045 shares of the biotechnology company’s stock valued at $12,950,000 after purchasing an additional 12,627 shares during the last quarter. Wedmont Private Capital lifted its holdings in shares of Axon Enterprise by 5.1% during the third quarter. Wedmont Private Capital now owns 909 shares of the biotechnology company’s stock valued at $650,000 after purchasing an additional 44 shares during the last quarter. Czech National Bank lifted its stake in Axon Enterprise by 10.3% in the 3rd quarter. Czech National Bank now owns 19,938 shares of the biotechnology company’s stock worth $14,308,000 after acquiring an additional 1,860 shares in the last quarter. Finally, Veracity Capital LLC lifted its stake in Axon Enterprise by 11.7% in the 3rd quarter. Veracity Capital LLC now owns 1,553 shares of the biotechnology company’s stock worth $1,114,000 after acquiring an additional 163 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.